A Multi-centre, Single-arm, Prospective Study to Assess Efficacy and Safety of Neoadjuvant Hormone Therapy Using Zoladex (Goserelin) and Casodex (Bicalutamide) in Patients With Advanced Prostate Cancer Undergoing Radical Prostatectomy.
Latest Information Update: 19 Dec 2022
At a glance
- Drugs Bicalutamide (Primary) ; Goserelin (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Sponsors AstraZeneca
Most Recent Events
- 14 Dec 2022 Status changed from active, no longer recruiting to discontinued.
- 23 Feb 2022 Status changed from recruiting to active, no longer recruiting.
- 06 Apr 2021 Planned End Date changed from 30 Oct 2022 to 1 Nov 2022.